ACCESS Newswire

Smart Eye

12.11.2021 13:16:30 CET | ACCESS Newswire | Press release

Share
Bulletin from Extraordinary General Meeting in Smart Eye Aktiebolag (publ)

GÖTEBORG, SE / ACCESSWIRE / November 12, 2021 / Smart Eye (STO:SEYE) (OTC PINK:SMTEF) (FRA:SE9)

At the extraordinary general meeting in Smart Eye Aktiebolag (publ), Reg. No. 556575-8371 (the "Company") held on 12 November 2021, the following resolutions were passed.

  • The extraordinary general meeting resolved to approve the board of directors' resolution on a directed share issue of not more than 329,534 shares, entailing an increase of the share capital by not more than SEK 32,953.40. The shares have, with deviation from the shareholders' pre-emption rights, been allotted to Carnegie Investment Bank AB (publ) on behalf of a number of institutional investors. The subscription price at the time of the board of directors' resolution amounted to SEK 183 per share and was established through negotiations with certain institutional investors and is considered to constitute a fair market price. The reason for the deviation from the shareholders' pre-emption rights is to enable a raise of capital in order to ensure to in a flexible and cost-efficient manner raise capital to use as means of payment for the acquisition of iMotions A/S.

Following registration with the Swedish Companies Registration Office, the total number of share and votes in the Company will amount to 21,129,157. The share issue entails a dilution of approximately 1.56 per cent of the number of shares and votes in the Company. The share capital will increase from SEK 2,079,962.30 to SEK 2,112,915.70.

  • The extraordinary general meeting resolved to authorise the board of directors to, on one or more occasions and with or without deviation from the shareholders' pre-emption rights, resolve on new share issues corresponding to the number of shares to be paid as consideration of the purchase price for the shares in iMotions A/S. Issues shall be carried out as in-kind issues. Issues may only be made on the terms agreed between the parties to the agreement to acquire the shares in iMotions A/S and the issue price shall be determined on market terms.

At the extraordinary general meeting, approximately 41 per cent of the votes were represented.

For further information, please contact
Martin Krantz, CEO Smart Eye AB
Phone: +46 70-329 26 98
Email: martin.krantz@smarteye.se

Anders Lyrheden, CFO Smart Eye AB
Phone: +46 70-320 96 95
Email: anders.lyrheden@smarteye.se

The information above was submitted for publication through the agency of the contact persons set out above, at 1.00 p.m. CET on 12 November 2021.

About Smart Eye
Smart Eye is the global leader in Human Insight AI, technology that understands, supports and predicts human behavior in complex environments. We bridge the gap between humans and machines for a safe and sustainable future.

Today, our technology is embedded in next-generation vehicles, leading the way towards human-centric mobility through Driver Monitoring Systems and Interior Sensing solutions. Our Research Instruments offer unparalleled insights into Automotive, Aviation & Aerospace, Assistive Technology, Media & Marketing, Psychology and many more fields. Our subsidiary Affectiva is pioneering Emotion AI, connecting machine logic with human empathy to gain a deeper understanding of how consumers engage with content and products.

Smart Eye was founded in 1999 and is headquartered in Sweden with offices in the US, UK, Germany, Egypt, Japan and China. A publicly traded company since 2016, our customers include NASA, Nissan, Boeing, Honeywell, Volvo, GM, BMW, Geely, Harvard University, 70% of the world's largest advertisers and 28% of the Fortune Global 500 companies.

SOURCE: Smart Eye



View source version on accesswire.com:
https://www.accesswire.com/672545/Bulletin-from-Extraordinary-General-Meeting-in-Smart-Eye-Aktiebolag-publ

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release

ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the

Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release

HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy

Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen

Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release

HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release

PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye